RRx-001 in Refractory Small-Cell Lung Carcinoma: A Case Report of a Partial Response after a Third Reintroduction of Platinum Doublets

RRx-001 is a pan-active, systemically nontoxic epigenetic inhibitor under investigation in advanced non-small cell lung cancer, small-cell lung cancer and high-grade neuroendocrine tumors in a Phase II clinical trial entitled TRIPLE THREAT (NCT02489903), which reexposes patients to previously effect...

Descripción completa

Detalles Bibliográficos
Autores principales: Carter, Corey A., Oronsky, Bryan T., Caroen, Scott Z., Scicinski, Jan J., Degesys, Aiste, Kim, Michelle M., Oronsky, Arnold L., Lybeck, Harry, Cabrales, Pedro, Oronsky, Neil, Reid, Tony, Roswarski, Joseph, Brzezniak, Christina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2016
Materias:
Published online: March, 2016
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4821137/
https://www.ncbi.nlm.nih.gov/pubmed/27065849
http://dx.doi.org/10.1159/000444631
Descripción
Sumario:RRx-001 is a pan-active, systemically nontoxic epigenetic inhibitor under investigation in advanced non-small cell lung cancer, small-cell lung cancer and high-grade neuroendocrine tumors in a Phase II clinical trial entitled TRIPLE THREAT (NCT02489903), which reexposes patients to previously effective but refractory platinum doublets after treatment with RRx-001. The purpose of this case study is first to report a partial response to carboplatin and etoposide in a patient with small-cell lung cancer pretreated with RRx-001, indicating episensitization or resensitization by epigenetic mechanisms, and second to discuss the literature related to small-cell lung cancer and episensitization.

Ejemplares similares